These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 34075790)
21. [Effect of ASCT2 gene knock-down by shRNA on biological behaviors of colorectal cancer cells]. Cai C; Zeng B; Zeng J; Xin H; Tang C Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):450-454. PubMed ID: 28440528 [TBL] [Abstract][Full Text] [Related]
22. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth. Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734 [TBL] [Abstract][Full Text] [Related]
23. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells. Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors. Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737 [TBL] [Abstract][Full Text] [Related]
25. 1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell. Zhou X; Zheng W; Nagana Gowda GA; Raftery D; Donkin SS; Bequette B; Teegarden D J Steroid Biochem Mol Biol; 2016 Oct; 163():147-56. PubMed ID: 27154413 [TBL] [Abstract][Full Text] [Related]
26. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2. Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158 [TBL] [Abstract][Full Text] [Related]
27. Ablation of the Bröer A; Gauthier-Coles G; Rahimi F; van Geldermalsen M; Dorsch D; Wegener A; Holst J; Bröer S J Biol Chem; 2019 Mar; 294(11):4012-4026. PubMed ID: 30635397 [TBL] [Abstract][Full Text] [Related]
28. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. Ren P; Yue M; Xiao D; Xiu R; Gan L; Liu H; Qing G J Pathol; 2015 Jan; 235(1):90-100. PubMed ID: 25142020 [TBL] [Abstract][Full Text] [Related]
29. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis. Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532 [TBL] [Abstract][Full Text] [Related]
30. AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis. Tao X; Lu Y; Qiu S; Wang Y; Qin J; Fan Z Cancer Lett; 2017 Nov; 408():33-42. PubMed ID: 28823958 [TBL] [Abstract][Full Text] [Related]
31. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Todorova VK; Kaufmann Y; Luo S; Klimberg VS Cancer Chemother Pharmacol; 2011 Feb; 67(2):285-91. PubMed ID: 20383709 [TBL] [Abstract][Full Text] [Related]
32. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5. Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232 [TBL] [Abstract][Full Text] [Related]
33. SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice. Zhao X; Petrashen AP; Sanders JA; Peterson AL; Sedivy JM Aging Cell; 2019 Jun; 18(3):e12947. PubMed ID: 30909319 [TBL] [Abstract][Full Text] [Related]
34. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. Bernhardt S; Bayerlová M; Vetter M; Wachter A; Mitra D; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Buchmann J; Weigert E; Bürrig KF; Thomssen C; Korf U; Beissbarth T; Wiemann S; Kantelhardt EJ Breast Cancer Res; 2017 Oct; 19(1):112. PubMed ID: 29020998 [TBL] [Abstract][Full Text] [Related]
35. The role of ASCT2 in cancer: A review. Liu Y; Zhao T; Li Z; Wang L; Yuan S; Sun L Eur J Pharmacol; 2018 Oct; 837():81-87. PubMed ID: 30025811 [TBL] [Abstract][Full Text] [Related]
36. Targeting SLC1A5 blocks cell proliferation through inhibition of mTORC1 in arsenite-treated human uroepithelial cells. Li S; Zhou Q; Liu W; Fu Z; Zhao H; Xi S Toxicol Lett; 2021 Jul; 345():1-11. PubMed ID: 33781819 [TBL] [Abstract][Full Text] [Related]
37. NEDD4L inhibits cell viability, cell cycle progression, and glutamine metabolism in esophageal squamous cell carcinoma via ubiquitination of c-Myc. Cheng W; Li G; Ye Z; Hu J; Gao L; Jia X; Zhao S; Wang Y; Zhou Q Acta Biochim Biophys Sin (Shanghai); 2022 May; 54(5):716-724. PubMed ID: 35593463 [TBL] [Abstract][Full Text] [Related]
38. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Jeon YJ; Khelifa S; Ratnikov B; Scott DA; Feng Y; Parisi F; Ruller C; Lau E; Kim H; Brill LM; Jiang T; Rimm DL; Cardiff RD; Mills GB; Smith JW; Osterman AL; Kluger Y; Ronai ZA Cancer Cell; 2015 Mar; 27(3):354-69. PubMed ID: 25759021 [TBL] [Abstract][Full Text] [Related]
39. Sorting nexin 27 (SNX27) regulates the trafficking and activity of the glutamine transporter ASCT2. Yang Z; Follett J; Kerr MC; Clairfeuille T; Chandra M; Collins BM; Teasdale RD J Biol Chem; 2018 May; 293(18):6802-6811. PubMed ID: 29563155 [TBL] [Abstract][Full Text] [Related]
40. Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. Ansari RE; Craze ML; Althobiti M; Alfarsi L; Ellis IO; Rakha EA; Green AR Br J Cancer; 2020 Jan; 122(1):94-101. PubMed ID: 31819174 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]